APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Prescription Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-Obesity Prescription Drugs Market Analysis and Forecast 2026-2032

21 December 2025199 pages

Choose your research edition.

Industry ResearchAnti-Obesity Prescription Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Prescription Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Prescription Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Prescription Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Prescription Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Anti-Obesity Prescription Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-Obesity Prescription Drugs include Novo Nordisk A/s, Glaxosmithkline, Vivus, Orexigen Therapeutics, F Hoffmann La Roche Ltd, Boehringer Ingelheim, Arena Pharmaceuticals and Alizyme, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-Obesity Prescription Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-Obesity Prescription Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-Obesity Prescription Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Obesity Prescription Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-Obesity Prescription Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-Obesity Prescription Drugs sales, projected growth trends, production technology, application and end-user industry.

Anti-Obesity Prescription Drugs Segment by Company

Novo Nordisk A/s

Glaxosmithkline

Vivus

Orexigen Therapeutics

F Hoffmann La Roche Ltd

Boehringer Ingelheim

Arena Pharmaceuticals

Alizyme

Anti-Obesity Prescription Drugs Segment by Type

Pediatric

Adult

Anti-Obesity Prescription Drugs Segment by Application

Hospitals Pharmacies

E-commerce

Retail Pharmacies

Anti-Obesity Prescription Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-Obesity Prescription Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Obesity Prescription Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pediatric Major Manufacturers Table 3. Adult Major Manufacturers Table 4. Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Pharmacies Major Manufacturers Table 6. E-commerce Major Manufacturers Table 7. Retail Pharmacies Major Manufacturers Table 8. Anti-Obesity Prescription Drugs Industry Trends Table 9. Anti-Obesity Prescription Drugs Industry Drivers Table 10. Anti-Obesity Prescription Drugs Industry Opportunities and Challenges Table 11. Anti-Obesity Prescription Drugs Industry Restraints Table 12. Global Anti-Obesity Prescription Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Anti-Obesity Prescription Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Anti-Obesity Prescription Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2021-2026) Table 16. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2027-2032) Table 17. Global Anti-Obesity Prescription Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Anti-Obesity Prescription Drugs Sales by Region (2021-2026) & (k units) Table 19. Global Anti-Obesity Prescription Drugs Sales by Region (2027-2032) & (k units) Table 20. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2021-2026) Table 21. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2027-2032) Table 22. Global Anti-Obesity Prescription Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Anti-Obesity Prescription Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Anti-Obesity Prescription Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Anti-Obesity Prescription Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global Anti-Obesity Prescription Drugs Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Anti-Obesity Prescription Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Anti-Obesity Prescription Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Anti-Obesity Prescription Drugs Manufacturers, Product Type & Application Table 30. Global Anti-Obesity Prescription Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Anti-Obesity Prescription Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Anti-Obesity Prescription Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-Obesity Prescription Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Anti-Obesity Prescription Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2021-2026) Table 37. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2027-2032) Table 38. Global Anti-Obesity Prescription Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 40. Global Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 41. Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2021-2026) Table 42. Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2027-2032) Table 43. Global Anti-Obesity Prescription Drugs Price by Type (2021-2026) & (US$/unit) Table 44. Global Anti-Obesity Prescription Drugs Price by Type (2027-2032) & (US$/unit) Table 45. Global Anti-Obesity Prescription Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Anti-Obesity Prescription Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Anti-Obesity Prescription Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2021-2026) Table 49. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2027-2032) Table 50. Global Anti-Obesity Prescription Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 52. Global Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 53. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2021-2026) Table 54. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2027-2032) Table 55. Global Anti-Obesity Prescription Drugs Price by Application (2021-2026) & (US$/unit) Table 56. Global Anti-Obesity Prescription Drugs Price by Application (2027-2032) & (US$/unit) Table 57. Novo Nordisk A/s Company Information Table 58. Novo Nordisk A/s Business Overview Table 59. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio Table 61. Novo Nordisk A/s Recent Development Table 62. Glaxosmithkline Company Information Table 63. Glaxosmithkline Business Overview Table 64. Glaxosmithkline Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio Table 66. Glaxosmithkline Recent Development Table 67. Vivus Company Information Table 68. Vivus Business Overview Table 69. Vivus Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Vivus Anti-Obesity Prescription Drugs Product Portfolio Table 71. Vivus Recent Development Table 72. Orexigen Therapeutics Company Information Table 73. Orexigen Therapeutics Business Overview Table 74. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio Table 76. Orexigen Therapeutics Recent Development Table 77. F Hoffmann La Roche Ltd Company Information Table 78. F Hoffmann La Roche Ltd Business Overview Table 79. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio Table 81. F Hoffmann La Roche Ltd Recent Development Table 82. Boehringer Ingelheim Company Information Table 83. Boehringer Ingelheim Business Overview Table 84. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio Table 86. Boehringer Ingelheim Recent Development Table 87. Arena Pharmaceuticals Company Information Table 88. Arena Pharmaceuticals Business Overview Table 89. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio Table 91. Arena Pharmaceuticals Recent Development Table 92. Alizyme Company Information Table 93. Alizyme Business Overview Table 94. Alizyme Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Alizyme Anti-Obesity Prescription Drugs Product Portfolio Table 96. Alizyme Recent Development Table 97. North America Anti-Obesity Prescription Drugs Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Anti-Obesity Prescription Drugs Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 100. North America Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 101. North America Anti-Obesity Prescription Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 102. North America Anti-Obesity Prescription Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 103. North America Anti-Obesity Prescription Drugs Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Anti-Obesity Prescription Drugs Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 106. North America Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 107. North America Anti-Obesity Prescription Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 108. North America Anti-Obesity Prescription Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 109. North America Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 111. North America Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 112. North America Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 113. North America Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 114. North America Anti-Obesity Prescription Drugs Sales by Country (2027-2032) & (k units) Table 115. North America Anti-Obesity Prescription Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 116. North America Anti-Obesity Prescription Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 117. United States Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 118. Canada Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 119. Mexico Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 120. Europe Anti-Obesity Prescription Drugs Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Anti-Obesity Prescription Drugs Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 123. Europe Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 124. Europe Anti-Obesity Prescription Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 125. Europe Anti-Obesity Prescription Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 126. Europe Anti-Obesity Prescription Drugs Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Anti-Obesity Prescription Drugs Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 129. Europe Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 130. Europe Anti-Obesity Prescription Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 131. Europe Anti-Obesity Prescription Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 132. Europe Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 134. Europe Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 135. Europe Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 136. Europe Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 137. Europe Anti-Obesity Prescription Drugs Sales by Country (2027-2032) & (k units) Table 138. Europe Anti-Obesity Prescription Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 139. Europe Anti-Obesity Prescription Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 140. Germany Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 141. France Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 142. U.K. Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 143. Italy Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 144. Russia Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 145. Spain Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 146. Netherlands Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 147. Switzerland Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 148. Sweden Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 149. Poland Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 150. China Anti-Obesity Prescription Drugs Revenue by Type (2021-2026) & (US$ Million) Table 151. China Anti-Obesity Prescription Drugs Revenue by Type (2027-2032) & (US$ Million) Table 152. China Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 153. China Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 154. China Anti-Obesity Prescription Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 155. China Anti-Obesity Prescription Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 156. China Anti-Obesity Prescription Drugs Revenue by Application (2021-2026) & (US$ Million) Table 157. China Anti-Obesity Prescription Drugs Revenue by Application (2027-2032) & (US$ Million) Table 158. China Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 159. China Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 160. China Anti-Obesity Prescription Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 161. China Anti-Obesity Prescription Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 162. Asia Anti-Obesity Prescription Drugs Revenue by Type (2021-2026) & (US$ Million) Table 163. Asia Anti-Obesity Prescription Drugs Revenue by Type (2027-2032) & (US$ Million) Table 164. Asia Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 165. Asia Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 166. Asia Anti-Obesity Prescription Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 167. Asia Anti-Obesity Prescription Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 168. Asia Anti-Obesity Prescription Drugs Revenue by Application (2021-2026) & (US$ Million) Table 169. Asia Anti-Obesity Prescription Drugs Revenue by Application (2027-2032) & (US$ Million) Table 170. Asia Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 171. Asia Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 172. Asia Anti-Obesity Prescription Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 173. Asia Anti-Obesity Prescription Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 174. Asia Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. Asia Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. Asia Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. Asia Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 178. Asia Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 179. Asia Anti-Obesity Prescription Drugs Sales by Country (2027-2032) & (k units) Table 180. Asia Anti-Obesity Prescription Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 181. Asia Anti-Obesity Prescription Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 182. Japan Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 183. South Korea Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 184. India Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 185. Australia Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 186. Taiwan Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 187. Southeast Asia Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 188. SAMEA Anti-Obesity Prescription Drugs Revenue by Type (2021-2026) & (US$ Million) Table 189. SAMEA Anti-Obesity Prescription Drugs Revenue by Type (2027-2032) & (US$ Million) Table 190. SAMEA Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 191. SAMEA Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 192. SAMEA Anti-Obesity Prescription Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 193. SAMEA Anti-Obesity Prescription Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 194. SAMEA Anti-Obesity Prescription Drugs Revenue by Application (2021-2026) & (US$ Million) Table 195. SAMEA Anti-Obesity Prescription Drugs Revenue by Application (2027-2032) & (US$ Million) Table 196. SAMEA Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 197. SAMEA Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 198. SAMEA Anti-Obesity Prescription Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 199. SAMEA Anti-Obesity Prescription Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 200. SAMEA Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 201. SAMEA Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 202. SAMEA Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 203. SAMEA Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 204. SAMEA Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 205. SAMEA Anti-Obesity Prescription Drugs Sales by Country (2027-2032) & (k units) Table 206. SAMEA Anti-Obesity Prescription Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 207. SAMEA Anti-Obesity Prescription Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 208. Brazil Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 209. Argentina Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 210. Chile Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 211. Colombia Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 212. Peru Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 213. Saudi Arabia Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 214. Israel Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 215. UAE Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 216. Turkey Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 217. Iran Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 218. Egypt Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Table 219. Key Raw Materials Table 220. Raw Materials Key Suppliers Table 221. Anti-Obesity Prescription Drugs Distributors List Table 222. Anti-Obesity Prescription Drugs Customers List Table 223. Research Programs/Design for This Report Table 224. Authors List of This Report Table 225. Secondary Sources Table 226. Primary Sources List of Figures Figure 1. Anti-Obesity Prescription Drugs Image Figure 2. Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Prescription Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pediatric Image Figure 5. Adult Image Figure 6. Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-Obesity Prescription Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Pharmacies Image Figure 9. E-commerce Image Figure 10. Retail Pharmacies Image Figure 11. Global Anti-Obesity Prescription Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Anti-Obesity Prescription Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global Anti-Obesity Prescription Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global Anti-Obesity Prescription Drugs Sales (2021-2032) & (k units) Figure 17. Global Anti-Obesity Prescription Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Anti-Obesity Prescription Drugs Sales YoY (2021-2032) & (k units) Figure 20. Europe Anti-Obesity Prescription Drugs Sales YoY (2021-2032) & (k units) Figure 21. China Anti-Obesity Prescription Drugs Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Anti-Obesity Prescription Drugs Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Anti-Obesity Prescription Drugs Sales YoY (2021-2032) & (k units) Figure 24. Global Anti-Obesity Prescription Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Anti-Obesity Prescription Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Anti-Obesity Prescription Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2021-2032) Figure 30. Global Anti-Obesity Prescription Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Anti-Obesity Prescription Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2021-2032) Figure 33. Global Anti-Obesity Prescription Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2021-2032) Figure 36. Global Anti-Obesity Prescription Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Anti-Obesity Prescription Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2021-2032) Figure 39. North America Anti-Obesity Prescription Drugs Revenue Share by Type (2021-2032) Figure 40. North America Anti-Obesity Prescription Drugs Sales Share by Type (2021-2032) Figure 41. North America Anti-Obesity Prescription Drugs Revenue Share by Application (2021-2032) Figure 42. North America Anti-Obesity Prescription Drugs Sales Share by Application (2021-2032) Figure 43. North America Anti-Obesity Prescription Drugs Revenue Share by Country (2021-2032) Figure 44. North America Anti-Obesity Prescription Drugs Sales Share by Country (2021-2032) Figure 45. Europe Anti-Obesity Prescription Drugs Revenue Share by Type (2021-2032) Figure 46. Europe Anti-Obesity Prescription Drugs Sales Share by Type (2021-2032) Figure 47. Europe Anti-Obesity Prescription Drugs Revenue Share by Application (2021-2032) Figure 48. Europe Anti-Obesity Prescription Drugs Sales Share by Application (2021-2032) Figure 49. Europe Anti-Obesity Prescription Drugs Revenue Share by Country (2021-2032) Figure 50. Europe Anti-Obesity Prescription Drugs Sales Share by Country (2021-2032) Figure 51. China Anti-Obesity Prescription Drugs Revenue Share by Type (2021-2032) Figure 52. China Anti-Obesity Prescription Drugs Sales Share by Type (2021-2032) Figure 53. China Anti-Obesity Prescription Drugs Revenue Share by Application (2021-2032) Figure 54. China Anti-Obesity Prescription Drugs Sales Share by Application (2021-2032) Figure 55. Asia Anti-Obesity Prescription Drugs Revenue Share by Type (2021-2032) Figure 56. Asia Anti-Obesity Prescription Drugs Sales Share by Type (2021-2032) Figure 57. Asia Anti-Obesity Prescription Drugs Revenue Share by Application (2021-2032) Figure 58. Asia Anti-Obesity Prescription Drugs Sales Share by Application (2021-2032) Figure 59. Asia Anti-Obesity Prescription Drugs Revenue Share by Country (2021-2032) Figure 60. Asia Anti-Obesity Prescription Drugs Sales Share by Country (2021-2032) Figure 61. SAMEA Anti-Obesity Prescription Drugs Revenue Share by Type (2021-2032) Figure 62. SAMEA Anti-Obesity Prescription Drugs Sales Share by Type (2021-2032) Figure 63. SAMEA Anti-Obesity Prescription Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Anti-Obesity Prescription Drugs Sales Share by Application (2021-2032) Figure 65. SAMEA Anti-Obesity Prescription Drugs Revenue Share by Country (2021-2032) Figure 66. SAMEA Anti-Obesity Prescription Drugs Sales Share by Country (2021-2032) Figure 67. Anti-Obesity Prescription Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Anti-Obesity Prescription Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric
  • Adult
Applications
  • Hospitals Pharmacies
  • E-commerce
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/s
  • Glaxosmithkline
  • Vivus
  • Orexigen Therapeutics
  • F Hoffmann La Roche Ltd
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-Obesity Prescription Drugs Market by Type
  3. 1.2.1 Global Anti-Obesity Prescription Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pediatric
  5. 1.2.3 Adult
  6. 1.3 Anti-Obesity Prescription Drugs Market by Application
  7. 1.3.1 Global Anti-Obesity Prescription Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals Pharmacies
  9. 1.3.3 E-commerce
  10. 1.3.4 Retail Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Anti-Obesity Prescription Drugs Market Dynamics
  1. 2.1 Anti-Obesity Prescription Drugs Industry Trends
  2. 2.2 Anti-Obesity Prescription Drugs Industry Drivers
  3. 2.3 Anti-Obesity Prescription Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Prescription Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-Obesity Prescription Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-Obesity Prescription Drugs Revenue by Region
  3. 3.2.1 Global Anti-Obesity Prescription Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-Obesity Prescription Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-Obesity Prescription Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-Obesity Prescription Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-Obesity Prescription Drugs Sales by Region
  9. 3.4.1 Global Anti-Obesity Prescription Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-Obesity Prescription Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-Obesity Prescription Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-Obesity Prescription Drugs Revenue by Manufacturers
  2. 4.1.1 Global Anti-Obesity Prescription Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-Obesity Prescription Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-Obesity Prescription Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-Obesity Prescription Drugs Sales by Manufacturers
  6. 4.2.1 Global Anti-Obesity Prescription Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-Obesity Prescription Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-Obesity Prescription Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-Obesity Prescription Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-Obesity Prescription Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-Obesity Prescription Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-Obesity Prescription Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Anti-Obesity Prescription Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-Obesity Prescription Drugs Market CR5 and HHI
  16. 4.8.2 2025 Anti-Obesity Prescription Drugs Tier 1, Tier 2, and Tier 3
5 Anti-Obesity Prescription Drugs Market by Type
  1. 5.1 Global Anti-Obesity Prescription Drugs Revenue by Type
  2. 5.1.1 Global Anti-Obesity Prescription Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-Obesity Prescription Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-Obesity Prescription Drugs Sales by Type
  6. 5.2.1 Global Anti-Obesity Prescription Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Obesity Prescription Drugs Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-Obesity Prescription Drugs Price by Type
6 Anti-Obesity Prescription Drugs Market by Application
  1. 6.1 Global Anti-Obesity Prescription Drugs Revenue by Application
  2. 6.1.1 Global Anti-Obesity Prescription Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-Obesity Prescription Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-Obesity Prescription Drugs Sales by Application
  6. 6.2.1 Global Anti-Obesity Prescription Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-Obesity Prescription Drugs Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-Obesity Prescription Drugs Price by Application
7 Company Profiles
  1. 7.1 Novo Nordisk A/s
  2. 7.1.1 Novo Nordisk A/s Company Information
  3. 7.1.2 Novo Nordisk A/s Business Overview
  4. 7.1.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
  6. 7.1.5 Novo Nordisk A/s Recent Developments
  7. 7.2 Glaxosmithkline
  8. 7.2.1 Glaxosmithkline Company Information
  9. 7.2.2 Glaxosmithkline Business Overview
  10. 7.2.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
  12. 7.2.5 Glaxosmithkline Recent Developments
  13. 7.3 Vivus
  14. 7.3.1 Vivus Company Information
  15. 7.3.2 Vivus Business Overview
  16. 7.3.3 Vivus Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Vivus Anti-Obesity Prescription Drugs Product Portfolio
  18. 7.3.5 Vivus Recent Developments
  19. 7.4 Orexigen Therapeutics
  20. 7.4.1 Orexigen Therapeutics Company Information
  21. 7.4.2 Orexigen Therapeutics Business Overview
  22. 7.4.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
  24. 7.4.5 Orexigen Therapeutics Recent Developments
  25. 7.5 F Hoffmann La Roche Ltd
  26. 7.5.1 F Hoffmann La Roche Ltd Company Information
  27. 7.5.2 F Hoffmann La Roche Ltd Business Overview
  28. 7.5.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
  30. 7.5.5 F Hoffmann La Roche Ltd Recent Developments
  31. 7.6 Boehringer Ingelheim
  32. 7.6.1 Boehringer Ingelheim Company Information
  33. 7.6.2 Boehringer Ingelheim Business Overview
  34. 7.6.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
  36. 7.6.5 Boehringer Ingelheim Recent Developments
  37. 7.7 Arena Pharmaceuticals
  38. 7.7.1 Arena Pharmaceuticals Company Information
  39. 7.7.2 Arena Pharmaceuticals Business Overview
  40. 7.7.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
  42. 7.7.5 Arena Pharmaceuticals Recent Developments
  43. 7.8 Alizyme
  44. 7.8.1 Alizyme Company Information
  45. 7.8.2 Alizyme Business Overview
  46. 7.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
  48. 7.8.5 Alizyme Recent Developments
8 North America
  1. 8.1 North America Anti-Obesity Prescription Drugs Market Size by Type
  2. 8.1.1 North America Anti-Obesity Prescription Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-Obesity Prescription Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-Obesity Prescription Drugs Price by Type (2021-2032)
  5. 8.2 North America Anti-Obesity Prescription Drugs Market Size by Application
  6. 8.2.1 North America Anti-Obesity Prescription Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-Obesity Prescription Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-Obesity Prescription Drugs Price by Application (2021-2032)
  9. 8.3 North America Anti-Obesity Prescription Drugs Market Size by Country
  10. 8.3.1 North America Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-Obesity Prescription Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-Obesity Prescription Drugs Market Size by Type
  2. 9.1.1 Europe Anti-Obesity Prescription Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-Obesity Prescription Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-Obesity Prescription Drugs Price by Type (2021-2032)
  5. 9.2 Europe Anti-Obesity Prescription Drugs Market Size by Application
  6. 9.2.1 Europe Anti-Obesity Prescription Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-Obesity Prescription Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-Obesity Prescription Drugs Price by Application (2021-2032)
  9. 9.3 Europe Anti-Obesity Prescription Drugs Market Size by Country
  10. 9.3.1 Europe Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-Obesity Prescription Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-Obesity Prescription Drugs Market Size by Type
  2. 10.1.1 China Anti-Obesity Prescription Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-Obesity Prescription Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Anti-Obesity Prescription Drugs Price by Type (2021-2032)
  5. 10.2 China Anti-Obesity Prescription Drugs Market Size by Application
  6. 10.2.1 China Anti-Obesity Prescription Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-Obesity Prescription Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Anti-Obesity Prescription Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-Obesity Prescription Drugs Market Size by Type
  2. 11.1.1 Asia Anti-Obesity Prescription Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-Obesity Prescription Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-Obesity Prescription Drugs Price by Type (2021-2032)
  5. 11.2 Asia Anti-Obesity Prescription Drugs Market Size by Application
  6. 11.2.1 Asia Anti-Obesity Prescription Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-Obesity Prescription Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-Obesity Prescription Drugs Price by Application (2021-2032)
  9. 11.3 Asia Anti-Obesity Prescription Drugs Market Size by Country
  10. 11.3.1 Asia Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-Obesity Prescription Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-Obesity Prescription Drugs Market Size by Type
  2. 12.1.1 SAMEA Anti-Obesity Prescription Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-Obesity Prescription Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-Obesity Prescription Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-Obesity Prescription Drugs Market Size by Application
  6. 12.2.1 SAMEA Anti-Obesity Prescription Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-Obesity Prescription Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-Obesity Prescription Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-Obesity Prescription Drugs Market Size by Country
  10. 12.3.1 SAMEA Anti-Obesity Prescription Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-Obesity Prescription Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-Obesity Prescription Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-Obesity Prescription Drugs Value Chain Analysis
  2. 13.1.1 Anti-Obesity Prescription Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-Obesity Prescription Drugs Production Mode & Process
  6. 13.2 Anti-Obesity Prescription Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-Obesity Prescription Drugs Distributors
  9. 13.2.3 Anti-Obesity Prescription Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst